CSPC Megalith Biopharmaceutical has entered into a license agreement with Radiance Biopharma for the development and ...

Co. Ltd. has described glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes, obesity, Alzheimer’s disease, overweight and nonalcoholic or metabolic ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Radiance Biopharma Inc. bought its way into the ROR1 antibody-drug conjugate (ADC) space through a potential $1 billion-plus licensing deal, including a $15 million up-front payment, with CSPC ...

Under the terms of the Exclusive License, Radiance will pay CSPC an upfront payment of $15 million, and up to $150 million in potential development and regulatory milestone payments and over $1 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Radiance Biopharma is heating up the ROR1 race. The U.S. biotech is paying China’s CSPC Megalith Biopharmaceutical $15 ...

A pre-election survey released by The SPARK ignites controversy and threats of censorship amid a public rebuke by a gubernatorial candidate calling the results 'fake' ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...